Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Muscle-invasive Urothelial Carcinoma of the Bladder”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06809140
What this trial is testing

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky 75
Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Testing effectiveness (Phase 2)Study completedNCT00045630
What this trial is testing

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 77
Large-scale testing (Phase 3)Study completedNCT00330499
What this trial is testing

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Who this might be right for
Transitional Cell Carcinoma of Urinary Bladder
Trans Tasman Radiation Oncology Group 67
Large-scale testing (Phase 3)Not Yet RecruitingNCT07464145
What this trial is testing

NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc. 393
Testing effectiveness (Phase 2)Study completedNCT00749892
What this trial is testing

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Who this might be right for
Recurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial Carcinoma+17 more
M.D. Anderson Cancer Center 34
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Post-approval studies (Phase 4)Looking for participantsNCT05962541
What this trial is testing

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Who this might be right for
Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza 327
Testing effectiveness (Phase 2)Study completedNCT03636256
What this trial is testing

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more
NanOlogy, LLC 36
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Not applicableNot Yet RecruitingNCT07744958
What this trial is testing

RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)

Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
Heinrich-Heine University, Duesseldorf 100
Early research (Phase 1)Active Not RecruitingNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 6
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07808216
What this trial is testing

Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT

Who this might be right for
Non Muscle Invasive Bladder Cancer
Tianjin First Central Hospital 54
Testing effectiveness (Phase 2)Study completedNCT02736266
What this trial is testing

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

Who this might be right for
Urothelial Bladder Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 174
Large-scale testing (Phase 3)Ended earlyNCT04688931
What this trial is testing

UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 282
Testing effectiveness (Phase 2)WithdrawnNCT07414992
What this trial is testing

Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Who this might be right for
Bladder Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT07480356
What this trial is testing

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics 284
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827612
What this trial is testing

Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUrologic NeoplasmsReceptor, Fibroblast Growth Factor, Type 3
Eli Lilly and Company 161
Not applicableStudy completedNCT01224665
What this trial is testing

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
SWOG Cancer Research Network 658
Next Page